Blair William & Co. IL Acquires 1,565 Shares of McKesson Corporation $MCK

Blair William & Co. IL raised its holdings in McKesson Corporation (NYSE:MCK) by 12.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,057 shares of the company’s stock after purchasing an additional 1,565 shares during the quarter. Blair William & Co. IL’s holdings in McKesson were worth $10,860,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Brighton Jones LLC lifted its stake in McKesson by 46.3% in the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after purchasing an additional 798 shares during the last quarter. Caxton Associates LLP acquired a new stake in McKesson in the first quarter valued at approximately $233,000. Sivia Capital Partners LLC grew its stake in shares of McKesson by 77.9% during the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock worth $502,000 after buying an additional 300 shares during the last quarter. Wedbush Securities Inc. increased its holdings in shares of McKesson by 6.5% during the second quarter. Wedbush Securities Inc. now owns 2,077 shares of the company’s stock worth $1,522,000 after buying an additional 126 shares in the last quarter. Finally, Penserra Capital Management LLC increased its holdings in shares of McKesson by 8.5% during the second quarter. Penserra Capital Management LLC now owns 690 shares of the company’s stock worth $504,000 after buying an additional 54 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the transaction, the executive vice president owned 3,247 shares of the company’s stock, valued at $3,214,530. This trade represents a 45.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,868 shares of company stock worth $3,743,820. Company insiders own 0.08% of the company’s stock.

McKesson Trading Up 2.4%

Shares of MCK opened at $941.19 on Tuesday. The stock’s 50-day moving average price is $884.77 and its two-hundred day moving average price is $819.18. McKesson Corporation has a 12 month low of $633.53 and a 12 month high of $999.00. The company has a market capitalization of $115.29 billion, a PE ratio of 27.07, a PEG ratio of 1.48 and a beta of 0.38.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities research analysts predict that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

Analyst Ratings Changes

MCK has been the topic of several recent research reports. TD Cowen raised their price objective on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a report on Thursday, February 5th. Wells Fargo & Company increased their target price on McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. lifted their price target on McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Raymond James Financial set a $970.00 price target on McKesson in a report on Thursday. Finally, Barclays upped their price objective on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $960.93.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.